RSS

B-cell mutation agent (BCMA)

The Food and Drug Administration (FDA) has granted breakthrough therapy designation to GlaxoSmithKline (GSK) for its investigational B-cell mutation agent (BCMA) monoclonal antibody-drug conjugate, for relapsed and refractory multiple myeloma more

News